Johnson & Johnson’s lead scientist said the company expects to have all data needed to file for authorization for its single-shot coronavirus vaccine candidate by February, according to a report.

Dr. Paul Stoffels, Johnson & Johnson’s chief scientific officer, reportedly told Reuters that the company expects to have 60,000 people enrolled in a late-stage trial, dubbed ENSEMBLE, by year’s end.

“And efficacy endpoint should be there in the first few weeks or months, January of February of the new year,” he told the news outlet.

Johnson & Johnson is several weeks behind competitors Moderna and Pfizer, with the latter announcing Wednesday that it would be filing for emergency use authorization “within days.” However, both Moderna and Pfizer are built on a two-dose model, whereas Johnson & Johnson’s JNJ-78436735 requires a single jab.

“In a pandemic, a single shot is definitely important globally,” Stoffels told …continued .
[Source: Fox News]